172 related articles for article (PubMed ID: 12891060)
1. Virological rebound after suppression on highly active antiretroviral therapy.
Mocroft A; Ruiz L; Reiss P; Ledergerber B; Katlama C; Lazzarin A; Goebel FD; Phillips AN; Clotet B; Lundgren JD;
AIDS; 2003 Aug; 17(12):1741-51. PubMed ID: 12891060
[TBL] [Abstract][Full Text] [Related]
2. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
3. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
4. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
Lucas GM; Chaisson RE; Moore RD
AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
[TBL] [Abstract][Full Text] [Related]
5. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.
Mocroft A; Phillips AN; Miller V; Gatell J; van Lunzen J; Parkin JM; Weber R; Roge B; Lazzarin A; Lundgren JD;
AIDS; 2001 Jan; 15(2):201-9. PubMed ID: 11216928
[TBL] [Abstract][Full Text] [Related]
6. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study).
Vandenhende MA; Perrier A; Bonnet F; Lazaro E; Cazanave C; Reigadas S; Chêne G; Morlat P;
Antivir Ther; 2015; 20(6):655-60. PubMed ID: 25735799
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication.
Ioannidis JP; Havlir DV; Tebas P; Hirsch MS; Collier AC; Richman DD
AIDS; 2000 Jul; 14(11):1481-8. PubMed ID: 10983634
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor.
Grabar S; Pradier C; Le Corfec E; Lancar R; Allavena C; Bentata M; Berlureau P; Dupont C; Fabbro-Peray P; Poizot-Martin I; Costagliola D
AIDS; 2000 Jan; 14(2):141-9. PubMed ID: 10708284
[TBL] [Abstract][Full Text] [Related]
9. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
Paredes R; Mocroft A; Kirk O; Lazzarin A; Barton SE; van Lunzen J; Katzenstein TL; Antunes F; Lundgren JD; Clotet B
Arch Intern Med; 2000 Apr; 160(8):1123-32. PubMed ID: 10789605
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
[TBL] [Abstract][Full Text] [Related]
11. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
12. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml.
Easterbrook PJ; Ives N; Waters A; Mullen J; O'Shea S; Peters B; Gazzard BG
AIDS; 2002 Jul; 16(11):1521-7. PubMed ID: 12131190
[TBL] [Abstract][Full Text] [Related]
13. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients.
Casado JL; Perez-Elías MJ; Antela A; Sabido R; Martí-Belda P; Dronda F; Blazquez J; Quereda C
AIDS; 1998 Jul; 12(11):F131-5. PubMed ID: 9708403
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
15. Virological response to protease inhibitor therapy in an HIV clinic cohort.
Staszewski S; Miller V; Sabin C; Carlebach A; Berger AM; Weidmann E; Helm EB; Hill A; Phillips A
AIDS; 1999 Feb; 13(3):367-73. PubMed ID: 10199227
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
Kirk O; Mocroft A; Pradier C; Bruun JN; Hemmer R; Clotet B; Miller V; Viard JP; Phillips AN; Lundgren JD;
AIDS; 2001 May; 15(8):999-1008. PubMed ID: 11399982
[TBL] [Abstract][Full Text] [Related]
17. The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load.
Lepri AC; Miller V; Phillips AN; Rabenau H; Sabin CA; Staszewski S
AIDS; 2001 Jan; 15(1):47-54. PubMed ID: 11192867
[TBL] [Abstract][Full Text] [Related]
18. Impact of low-level viraemia on virological failure among Asian children with perinatally acquired HIV on first-line combination antiretroviral treatment: a multicentre, retrospective cohort study.
Sudjaritruk T; Teeraananchai S; Kariminia A; Lapphra K; Kumarasamy N; Fong MS; Hansudewechakul R; Bunupuradah T; Ly PS; Nallusamy RA; Sohn AH; Sirisanthana V;
J Int AIDS Soc; 2020 Jul; 23(7):e25550. PubMed ID: 32628816
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.
d'Arminio Monforte A; Testa L; Adorni F; Chiesa E; Bini T; Moscatelli GC; Abeli C; Rusconi S; Sollima S; Balotta C; Musicco M; Galli M; Moroni M
AIDS; 1998 Sep; 12(13):1631-7. PubMed ID: 9764782
[TBL] [Abstract][Full Text] [Related]
20. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
d'Arminio Monforte A; Lepri AC; Rezza G; Pezzotti P; Antinori A; Phillips AN; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
AIDS; 2000 Mar; 14(5):499-507. PubMed ID: 10780712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
